A Phase 1 interventional study of Selpercatinib and Moxifloxacin in Healthy, sponsored by Eli Lilly and Company. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-09-18.
Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The main purpose of this study is to assess the effect of Selpercatinib (LY3527723) on the heart rate-corrected QT (QTc) interval. The study will last up to 41 days.
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Period 1: 320 milligram (mg) Selpercatinib and Selpercatinib matching placebo (Treatment A) Period 2: 640 mg Selpercatinib (Treatment B) Period 3: 400 mg moxifloxacin (Treatment C) Period 4: Selpercatinib matching placebo (Treatment D) Participants received their assigned treatments in each of the above treatment period on Day 1 orally.
Drug: Selpercatinib
Period 1: 640 mg Selpercatinib (Treatment B) Period 2: Selpercatinib matching placebo (Treatment D) Period 3: 320 mg Selpercatinib and Selpercatinib matching placebo (Treatment A) Period 4: 400 mg moxifloxacin (Treatment C) Participants received their assigned treatments in each of the above treatment period on Day 1 orally.
Drug: Selpercatinib
Period 1: 400 mg moxifloxacin (Treatment C) Period 2: Selpercatinib matching placebo (Treatment D) Period 3: 320 mg Selpercatinib and Selpercatinib matching placebo (Treatment A) Period 4: 640 mg Selpercatinib (Treatment B) Participants received their assigned treatments in each of the above treatment period on Day 1 orally. Period Title: Treatment Period 1
Drug: Moxifloxacin
Period 1: Selpercatinib matching placebo (Treatment D) Period 2: 400 mg moxifloxacin (Treatment C) Period 3: 640 mg Selpercatinib (Treatment B) Period 4: 320 mg Selpercatinib and Selpercatinib matching placebo (Treatment A) Participants received their assigned treatments in each of the above treatment period on Day 1 orally.
Drug: Placebo
Administered orally
Also known as: LY3527723, LOXO-292
Administered orally
Administered orally.
Cardiodynamics: Placebo-corrected Change From Baseline in QT Interval Corrected Using Fridericia's Correction (QTcF) (ΔΔQTcF) for Treatments A, B, and C
The cardiodynamic assessment was performed through 12-lead electrocardiogram (ECG) extracted from continuous recordings at pre-specified time points. Participants rested in supine position for at least 10 minutes prior to and 5 minutes after each time point for ECG extractions. The QT interval is the time from electrocardiogram Q wave to the end of the T wave corresponding to electrical systole. QT interval was corrected for heart rate using QTcF. Placebo-corrected change from baseline in QTcF (ΔΔQTcF) was calculated based on model-predicted effect
Time frame: Pre-dose, -0.25, -0.5, -0.25, 0.25, 0.5, 0.75, 1.5, 2, 2.5, 3, 4, 7, 9, 12, and 24 hours post-dose
Pharmacokinetics (PK): Area Under the Concentration-time Curve From Time 0 to the Time of the Last Observed Non-zero Concentration (AUC0-t) of Selpercatinib
PK: AUC0-t of Selpercatinib is reported.
Time frame: Pre-dose, 0.25, 0.5, 0.75, 1.5, 2, 2.5, 3, 4, 7, 9, 12, 24, 36, 48, 72, 96, 120, 144, 168, 192, 216, and 240 hours postdose
PK: Area Under the Concentration-time Curve From Time 0 Extrapolated to Infinity (AUC0-inf) of Selpercatinib
PK: AUC0-inf of Selpercatinib is reported.
Time frame: Pre-dose, 0.25, 0.5, 0.75, 1.5, 2, 2.5, 3, 4, 7, 9, 12, 24, 36, 48, 72, 96, 120, 144, 168, 192, 216, and 240 hours postdose
PK: Percent of AUC0-inf Extrapolated (AUC%Extrap) of Selpercatinib
PK: AUC%extrap of Selpercatinib is reported.
Time frame: Pre-dose, 0.25, 0.5, 0.75, 1.5, 2, 2.5, 3, 4, 7, 9, 12, 24, 36, 48, 72, 96, 120, 144, 168, 192, 216, and 240 hours postdose
PK: Maximum Observed Concentration (Cmax) of Selpercatinib
PK: Cmax of Selpercatinib is reported.
Time frame: Pre-dose, 0.25, 0.5, 0.75, 1.5, 2, 2.5, 3, 4, 7, 9, 12, 24, 36, 48, 72, 96, 120, 144, 168, 192, 216, and 240 hours postdose
PK: Time to Reach Cmax (Tmax) of Selpercatinib
PK: Tmax of Selpercatinib is reported.
Time frame: Pre-dose, 0.25, 0.5, 0.75, 1.5, 2, 2.5, 3, 4, 7, 9, 12, 24, 36, 48, 72, 96, 120, 144, 168, 192, 216, and 240 hours postdose
PK: Apparent First Order Terminal Elimination Rate Constant (Kel) of Selpercatinib
PK: Kel of Selpercatinib is reported.
Time frame: Pre-dose, 0.25, 0.5, 0.75, 1.5, 2, 2.5, 3, 4, 7, 9, 12, 24, 36, 48, 72, 96, 120, 144, 168, 192, 216, and 240 hours postdose
PK: Apparent First-order Terminal Elimination Half-life (t½) of Selpercatinib
PK: t½ of Selpercatinib is reported.
Time frame: Pre-dose, 0.25, 0.5, 0.75, 1.5, 2, 2.5, 3, 4, 7, 9, 12, 24, 36, 48, 72, 96, 120, 144, 168, 192, 216, and 240 hours postdose
| Milestone | Treatment Sequence 1: ABCD | Treatment Sequence 2: BDAC | Treatment Sequence 3: CADB | Treatment Sequence 4: DCBA |
|---|---|---|---|---|
| Started | 8 | 8 | 8 | 8 |
| Received at least one dose of study drug | 8 | 8 | 8 | 8 |
| Completed | 8 | 8 | 8 | 8 |
| Not completed | 0 | 0 | 0 | 0 |
| Milestone | Treatment Sequence 1: ABCD | Treatment Sequence 2: BDAC | Treatment Sequence 3: CADB | Treatment Sequence 4: DCBA |
|---|---|---|---|---|
| Started | 8 | 8 | 8 | 8 |
| Received at least one dose of study drug | 8 | 8 | 8 | 8 |
| Completed | 8 | 8 | 8 | 8 |
| Not completed | 0 | 0 | 0 | 0 |
| Milestone | Treatment Sequence 1: ABCD | Treatment Sequence 2: BDAC | Treatment Sequence 3: CADB | Treatment Sequence 4: DCBA |
|---|---|---|---|---|
| Started | 8 | 8 | 8 | 8 |
| Received at least one dose of study drug | 8 | 8 | 8 | 8 |
| Completed | 8 | 8 | 8 | 8 |
| Not completed | 0 | 0 | 0 | 0 |
| Milestone | Treatment Sequence 1: ABCD | Treatment Sequence 2: BDAC | Treatment Sequence 3: CADB | Treatment Sequence 4: DCBA |
|---|---|---|---|---|
| Started | 8 | 8 | 8 | 8 |
| Received at least one dose of study drug | 8 | 8 | 8 | 8 |
| Completed | 8 | 8 | 8 | 8 |
| Not completed | 0 | 0 | 0 | 0 |
The cardiodynamic assessment was performed through 12-lead electrocardiogram (ECG) extracted from continuous recordings at pre-specified time points. Participants rested in supine position for at least 10 minutes prior to and 5 minutes after each time point for ECG extractions. The QT interval is the time from electrocardiogram Q wave to the end of the T wave corresponding to electrical systole. QT interval was corrected for heart rate using QTcF. Placebo-corrected change from baseline in QTcF (ΔΔQTcF) was calculated based on model-predicted effect
| milliseconds | 320 mg Selpercatinib (Treatment A) | 640 mg Selpercatnib (Treatment B) | 400 mg Moxifloxacin (Treatment C) |
|---|---|---|---|
| Cardiodynamics: Placebo-corrected Change From Baseline in QT Interval Corrected Using Fridericia's Correction (QTcF) (ΔΔQTcF) for Treatments A, B, and C | 3.4 (0.40 to 6.34) | 4.4 (1.37 to 7.40) | 6.4 (3.38 to 9.43) |
PK: AUC0-t of Selpercatinib is reported.
| nanogram*hour per millilitre (ng*h/mL) | 320 mg Selpercatinib (Treatment A) | 640 mg Selpercatnib (Treatment B) |
|---|---|---|
| Pharmacokinetics (PK): Area Under the Concentration-time Curve From Time 0 to the Time of the Last Observed Non-zero Concentration (AUC0-t) of Selpercatinib | 33730 ± 42.3 | 42670 ± 65.8 |
PK: AUC0-inf of Selpercatinib is reported.
| ng*hr/mL | 320 mg Selpercatinib (Treatment A) | 640 mg Selpercatnib (Treatment B) |
|---|---|---|
| PK: Area Under the Concentration-time Curve From Time 0 Extrapolated to Infinity (AUC0-inf) of Selpercatinib | 33830 ± 42.3 | 42830 ± 65.7 |
PK: AUC%extrap of Selpercatinib is reported.
| percentage of AUC0-inf extrapolated | 320 mg Selpercatinib (Treatment A) | 640 mg Selpercatnib (Treatment B) |
|---|---|---|
| PK: Percent of AUC0-inf Extrapolated (AUC%Extrap) of Selpercatinib | 0.2986 ± 0.21464 | 0.3734 ± 0.53500 |
PK: Cmax of Selpercatinib is reported.
| nanogram per milliliter (ng/mL) | 320 mg Selpercatinib (Treatment A) | 640 mg Selpercatnib (Treatment B) |
|---|---|---|
| PK: Maximum Observed Concentration (Cmax) of Selpercatinib | 2024 ± 74.6 | 2356 ± 103.0 |
PK: Tmax of Selpercatinib is reported.
| hour | 320 mg Selpercatinib (Treatment A) | 640 mg Selpercatnib (Treatment B) |
|---|---|---|
| PK: Time to Reach Cmax (Tmax) of Selpercatinib | 1.557 (0.80 to 24.06) | 2.051 (0.82 to 4.09) |
PK: Kel of Selpercatinib is reported.
| 1/hour | 320 mg Selpercatinib (Treatment A) | 640 mg Selpercatnib (Treatment B) |
|---|---|---|
| PK: Apparent First Order Terminal Elimination Rate Constant (Kel) of Selpercatinib | 0.02515 ± 0.0087987 | 0.02459 ± 0.0070524 |
PK: t½ of Selpercatinib is reported.
| hour | 320 mg Selpercatinib (Treatment A) | 640 mg Selpercatnib (Treatment B) |
|---|---|---|
| PK: Apparent First-order Terminal Elimination Half-life (t½) of Selpercatinib | 31.189 ± 11.6988 | 30.582 ± 9.2791 |
Collected over Baseline up to 41 Days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 320 mg Selpercatinib | 0/32 (0%) | 0/32 (0%) | 6/32 (18.8%) |
| 640 mg Selpercatinib | 0/32 (0%) | 0/32 (0%) | 2/32 (6.3%) |
| 400 mg Moxifloxacin | 0/32 (0%) | 0/32 (0%) | 0/32 (0%) |
| Selpercatinib Matching Placebo | 0/32 (0%) | 0/32 (0%) | 4/32 (12.5%) |
| Event | 320 mg Selpercatinib | 640 mg Selpercatinib | 400 mg Moxifloxacin | Selpercatinib Matching Placebo |
|---|---|---|---|---|
| ConstipationGastrointestinal disorders | 2/32 | 0/32 | 0/32 | 4/32 |
| NauseaGastrointestinal disorders | 2/32 | 0/32 | 0/32 | 0/32 |
| Vessel puncture site painGeneral disorders | 0/32 | 2/32 | 0/32 | 0/32 |
| Nasal congestionRespiratory, thoracic and mediastinal disorders | 2/32 | 0/32 | 0/32 | 0/32 |
All randomized participants.
| Age, Continuous(years) | Treatment Sequence 1: ABCD | Treatment Sequence 2: BDAC | Treatment Sequence 3: CADB | Treatment Sequence 4: DCBA | Total |
|---|---|---|---|---|---|
| Mean | 35.0 ± 11.44 | 40.3 ± 8.78 | 44.0 ± 8.88 | 10.18 ± 10.18 | 40.5 ± 10.02 |
| Sex: Female, Male(Participants) | Treatment Sequence 1: ABCD | Treatment Sequence 2: BDAC | Treatment Sequence 3: CADB | Treatment Sequence 4: DCBA | Total |
|---|---|---|---|---|---|
| Female | 7 | 8 | 6 | 5 | 26 |
| Male | 1 | 0 | 2 | 3 | 6 |
| Ethnicity (NIH/OMB)(Participants) | Treatment Sequence 1: ABCD | Treatment Sequence 2: BDAC | Treatment Sequence 3: CADB | Treatment Sequence 4: DCBA | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 2 | 4 | 4 | 4 | 14 |
| Not Hispanic or Latino | 6 | 4 | 4 | 4 | 18 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Treatment Sequence 1: ABCD | Treatment Sequence 2: BDAC | Treatment Sequence 3: CADB | Treatment Sequence 4: DCBA | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 1 | 0 | 0 | 1 |
| Asian | 0 | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 1 | 0 | 0 | 0 | 1 |
| Black or African American | 1 | 1 | 2 | 0 | 4 |
| White | 5 | 6 | 6 | 8 | 25 |
| More than one race | 1 | 0 | 0 | 0 | 1 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Region of Enrollment(Participants) | Treatment Sequence 1: ABCD | Treatment Sequence 2: BDAC | Treatment Sequence 3: CADB | Treatment Sequence 4: DCBA | Total |
|---|---|---|---|---|---|
| United States | 8 | 8 | 8 | 8 | 32 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Apr 2019 to primary completion in Jun 2019, 2 months.
Results were first posted in Sep 2025, 6 years 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Selpercatinib